RDHL

Opaganib (ABC294640, Yeliva®)

COVID-19

Phase 2/3 (Preliminary Data)

Exp Date

Q4 2020

Amp Volatility Score

Catalyst Info & Data Links

TITLE: Opaganib (ABC294640, Yeliva®) in COVID - Phase 2/3 (Preliminary Data)

  • ClinicalTrial.gov (NCT04467840): Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia


WHAT IS THE CATALYST EVENT?

  • Phase 2/3 Preliminary Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Q4 2020


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION / RATIONALE

  • Opaganib (Yeliva®, ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities. Opaganib is an investigational drug targeting several potential oncology, inflammatory and gastrointestinal indications (Learn more).

Updated by HC

#RDHL, #Opaganib, #ABC294640, #Yeliva®, #COVID

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

RDHL - Positive Recommendation...

#RDHL announced that its U.S. Phase 2 study with #opaganib (#Yeliva®, #ABC294640)1 in patients hospitalized with severe #COVID-19 pneumonia, has successfully passed the first scheduled independent Saf...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon